JP2022519789A5 - - Google Patents
Info
- Publication number
- JP2022519789A5 JP2022519789A5 JP2021569596A JP2021569596A JP2022519789A5 JP 2022519789 A5 JP2022519789 A5 JP 2022519789A5 JP 2021569596 A JP2021569596 A JP 2021569596A JP 2021569596 A JP2021569596 A JP 2021569596A JP 2022519789 A5 JP2022519789 A5 JP 2022519789A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- hydroxyvitamin
- serum
- composition according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024204631A JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802148P | 2019-02-06 | 2019-02-06 | |
| US62/802,148 | 2019-02-06 | ||
| PCT/IB2020/000089 WO2020161543A1 (en) | 2019-02-06 | 2020-02-06 | Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024204631A Division JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519789A JP2022519789A (ja) | 2022-03-24 |
| JP2022519789A5 true JP2022519789A5 (enExample) | 2023-02-14 |
Family
ID=69903711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569596A Pending JP2022519789A (ja) | 2019-02-06 | 2020-02-06 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
| JP2024204631A Pending JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024204631A Pending JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220226351A1 (enExample) |
| EP (1) | EP3920938A1 (enExample) |
| JP (2) | JP2022519789A (enExample) |
| KR (1) | KR20210126023A (enExample) |
| CN (1) | CN113573714A (enExample) |
| AU (2) | AU2020218639A1 (enExample) |
| CA (1) | CA3128153A1 (enExample) |
| MX (1) | MX2020011741A (enExample) |
| WO (1) | WO2020161543A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025094144A1 (en) | 2023-11-02 | 2025-05-08 | Eirgen Pharma Ltd. | Controlling loss of kidney function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593047T3 (es) * | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
| ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
| KR20190028822A (ko) * | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| HUE073014T2 (hu) | 2007-04-25 | 2025-12-28 | Opko Renal Llc | Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén |
| US11752158B2 (en) * | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| EP2281058B1 (en) | 2008-04-02 | 2016-06-29 | Opko Ireland Global Holdings, Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| AU2013203489B2 (en) * | 2008-07-24 | 2015-02-05 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration |
| WO2011123476A1 (en) * | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ治療法 |
| AU2019248829B2 (en) * | 2018-04-03 | 2025-02-06 | Opko Ireland Global Holdings, Ltd. | Use of calcifediol in bariatric surgery patients |
-
2020
- 2020-02-06 MX MX2020011741A patent/MX2020011741A/es unknown
- 2020-02-06 US US17/429,278 patent/US20220226351A1/en active Pending
- 2020-02-06 WO PCT/IB2020/000089 patent/WO2020161543A1/en not_active Ceased
- 2020-02-06 KR KR1020217026559A patent/KR20210126023A/ko not_active Ceased
- 2020-02-06 AU AU2020218639A patent/AU2020218639A1/en not_active Abandoned
- 2020-02-06 CA CA3128153A patent/CA3128153A1/en active Pending
- 2020-02-06 CN CN202080020844.6A patent/CN113573714A/zh active Pending
- 2020-02-06 JP JP2021569596A patent/JP2022519789A/ja active Pending
- 2020-02-06 EP EP20713085.7A patent/EP3920938A1/en active Pending
-
2024
- 2024-11-25 JP JP2024204631A patent/JP2025031720A/ja active Pending
-
2025
- 2025-10-30 AU AU2025259887A patent/AU2025259887A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adachi et al. | Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. | |
| JP2017075183A5 (enExample) | ||
| JP3529790B2 (ja) | 続発性上皮小体機能亢進症の治療のための薬剤の製造におけるビタミンｄ▲下２▼又はビタミンｄ▲下４▼誘導体の用途 | |
| Castro et al. | Human immune globulin infusion in Guillain‐Barré syndrome: Worsening during and after treatment | |
| EP3542792A1 (en) | Controlled release 25-hydroxyvitamin d | |
| JP2010525080A5 (enExample) | ||
| CN101668532B (zh) | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途 | |
| FI3225243T3 (fi) | Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä | |
| JP2017002086A5 (enExample) | ||
| SI2679228T1 (en) | THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D | |
| Tsukamoto et al. | Pharmacological parathyroidectomy by oral 1, 25 (OH) 2D3 pulse therapy | |
| Ludwig et al. | Supportive care in multiple myeloma | |
| EP0301167A1 (en) | A combination of cholecalciferol derivatives for the treatment of renal bone disease | |
| Godoy et al. | Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? | |
| Öhqvist et al. | A comparison between morphine, meperidine and ketobemidone in continuous intravenous infusion for postoperative relief | |
| EP2488642B1 (en) | Compositions and methods for the treatment of drug-induced hand-foot syndrome | |
| JP2022519789A5 (enExample) | ||
| AU2005269362A1 (en) | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate | |
| JP2025031720A5 (enExample) | ||
| AU2010261967A1 (en) | New therapeutical uses of inecalcitol | |
| JP2021522241A5 (enExample) | ||
| Salim et al. | Denosumab-associated severe hypocalcemia in a patient with chronic kidney disease | |
| van der Meche et al. | Guillain-Barre Syndrome | |
| WO2003055496A1 (en) | Method for the treatment of bone disorders | |
| JP2004517032A (ja) | Ｉｃｕ関連低カルシウム血症のビタミンｄ化合物による治療 |